Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. [PDF]
PLoS ONE, 2014 PurposeDespite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance.
Hiromi I Wettersten +5 more
doaj +7 more sources
Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1 [PDF]
Scientific Reports, 2018 TDP-43 and FUS are nuclear proteins with multiple functions in mRNA processing. They play key roles in ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia), where they are partially lost from the nucleus and aggregate in the cytoplasm of
Helena Ederle +7 more
doaj +7 more sources
P006 (0037) RECURRENT EXPORTIN 1 MUTATIONS IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA [PDF]
HemaSphere, 2018 doaj +3 more sources
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma [PDF]
Neuro-Oncology, 2015 Glioblastoma (GBM) is poorly responsive to current chemotherapy. The nuclear transporter exportin 1 (XPO1, CRM1) is often highly expressed in GBM, which may portend a poor prognosis. Here, we determine the efficacy of novel selective inhibitors of nuclear export (SINE) specific to XPO1 in preclinical models of GBM.Seven patient-derived GBM lines were ...
Jessie Hao-Ru Hsu, Cecile L Maire
exaly +5 more sources
In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals. [PDF]
PLoS ONE, 2018 Infection of immunocompromised individuals with normally benign opportunistic viruses is a major health burden globally. Infections with viruses such as Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Kaposi's sarcoma virus (KSHV), adenoviruses ...
Douglas G Widman +3 more
doaj +2 more sources
Therapeutic Targeting of Exportin-1 in Childhood Cancer. [PDF]
Cancers (Basel), 2021 Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers.
Galinski B +6 more
europepmc +4 more sources
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers [PDF]
Science Translational Medicine, 2023 Álvaro Quintanal-Villalonga +2 more
exaly +2 more sources
Exportin 1 inhibition as antiviral therapy. [PDF]
Drug Discov Today, 2020 Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the ...
Uddin MH, Zonder JA, Azmi AS.
europepmc +3 more sources
Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy (Review). [PDF]
Med Int (Lond), 2022 Nuclear pore complexes (NPCs) regulate the entry and exit of molecules from the cell nucleus. Small molecules pass through NPCs by diffusion while large molecules enter and exit the nucleus by karyopherins, which serve as transport factors. Exportin-1 (XPO1) is a protein that is an important member of the karyopherin family and carries macromolecules ...
Özdaş S, Canatar İ.
europepmc +4 more sources
Therapeutic targeting of exportin-1 beyond nuclear export. [PDF]
Trends Pharmacol SciExportin-1 (XPO1), also known as chromosome region maintenance 1 (CRM1), directly binds to and mediates the nuclear export of hundreds of cargo proteins. Blocking nuclear export by the selective inhibitors of nuclear export (SINEs) is a validated therapeutic axis in cancer and an active area of research.
Chen YF, Adams DJ.
europepmc +3 more sources